Mirtazapine

Mirtazapine is a tetracyclic antidepressant that is usually grouped as a noradrenergic and specific serotonergic antidepressant, abbreviated NaSSA. Unlike the selective serotonin reuptake inhibitors that dominate antidepressant prescribing, it does not block the reuptake of serotonin, norepinephrine or dopamine and does not inhibit monoamine oxidase; instead it produces its effects by antagonizing several neurotransmitter receptors ^[1].

The drug was synthesized in 1989 by the pharmaceutical company Organon. It was first approved in the Netherlands in 1994 and reached the United States market in 1996 under the brand name Remeron, with generic versions following after its patent expired in the mid-2000s ^[1]. Mirtazapine is well absorbed when taken by mouth and has a long elimination half-life that supports once-daily dosing, and it is metabolized in the liver by several cytochrome P450 enzymes ^[2].

Its principal approved use is the treatment of major depressive disorder in adults. Comparative reviews have found its antidepressant efficacy broadly similar to that of tricyclic antidepressants and, in some analyses, faster in onset and at least as effective as the SSRIs, and a large network meta-analysis ranked it among the more effective antidepressants ^[1][3][4]. Because of its distinctive effects it is also used off-label for several purposes, most commonly as a sleep aid, since it is strongly sedating, and as an appetite stimulant in people who are underweight or troubled by nausea; it has additionally been used for anxiety symptoms ^[1]. Two features set it apart from the SSRIs: it commonly increases appetite and body weight, and it carries a lower likelihood of sexual dysfunction ^[1][3].

Mirtazapine is a prescription-only medicine available as conventional tablets and as orally disintegrating tablets. Like other antidepressants it carries warnings about a possible increase in suicidal thoughts in younger patients early in treatment. It is also used in veterinary practice, notably to stimulate appetite in cats ^[1].

Mirtazapine is a prescription antidepressant. Common effects include drowsiness, increased appetite and weight gain, dry mouth, dizziness and higher cholesterol or triglycerides. Rare but serious risks include a drop in white blood cells known as agranulocytosis, and serotonin syndrome when combined with other serotonergic drugs. It should not be used with or near a course of MAO inhibitors, and alcohol or other sedatives add to its drowsiness; stopping abruptly can trigger discontinuation symptoms.

Mirtazapine undergoes hepatic metabolism via multiple CYP450 enzymes, and its clearance is substantially reduced by CYP2D6 and CYP3A4 inhibitors. When combined with paroxetine, mirtazapine's apparent clearance drops by approximately 27 percent, requiring dose reduction to avoid accumulation ^[23]. The interaction is even more pronounced with fluvoxamine, which causes a 51 percent reduction in mirtazapine clearance; this is a pharmacokinetic interaction where the SSRI inhibits the enzyme responsible for mirtazapine's elimination ^[23]. Body weight also modulates this interaction; obesity further reduces clearance independent of the SSRI effect, suggesting additive metabolic impairment.

The documented interactions are limited to CYP2D6 and CYP3A4 inhibitors, primarily other psychiatric drugs. Alcohol has not been specifically studied in combination with mirtazapine for formal pharmacokinetic interaction. Most other medications lack documented interaction data with mirtazapine, leaving their combinations understudied.

Checking a whole stack? Run it through interactions + stacks.

Mirtazapine was developed by the Dutch pharmaceutical company Organon, emerging from a chemical program related to the earlier antidepressant mianserin. Chemists sought a compound that would enhance both noradrenergic and serotonergic transmission through receptor blockade rather than reuptake inhibition, and mirtazapine was the result. It was first introduced in the Netherlands in 1994 and received US FDA approval in 1996, marketed under the brand name Remeron. It was positioned as a noradrenergic and specific serotonergic antidepressant (NaSSA), a novel mechanistic class at the time. An orally disintegrating formulation, Remeron SolTab, later broadened its use, and the drug is now widely available as a low-cost generic.

Mirtazapine holds a respected place in psychiatry as an effective antidepressant with a distinctive profile that suits particular patients well. In the landmark 2018 Cipriani network meta-analysis of 21 antidepressants, mirtazapine ranked among the more efficacious agents in head-to-head comparisons. Its sedating and appetite-stimulating effects, arising from potent histamine H1 blockade, are often turned to advantage in depressed patients troubled by insomnia, anxiety, poor appetite, or weight loss. Because it does not inhibit serotonin reuptake, it tends to cause less sexual dysfunction and gastrointestinal upset than SSRIs, a genuine benefit for many. It is honest to acknowledge that weight gain and daytime drowsiness are common and lead some to discontinue it. On balance it remains a valued, well-understood option, especially where its side effects align with a patient's needs.